

Table 14-1.01  
Summary of Populations

	Placebo (N=86)	Xanomeline Low Dose (N=84)	Xanomeline High Dose (N=84)	Total (N=254)
Intent-To-Treat (ITT)	86 (100%)	84 (100%)	84 (100%)	254 (100%)
Safety	86 (100%)	84 (100%)	84 (100%)	254 (100%)
Efficacy	79 ( 92%)	81 ( 96%)	74 ( 88%)	234 ( 92%)
Complete Week 24	60 ( 70%)	28 ( 33%)	30 ( 36%)	118 ( 46%)
Complete Study	58 ( 67%)	25 ( 30%)	27 ( 32%)	110 ( 43%)

NOTE: N in column headers represents number of subjects entered in study (i.e., signed informed consent). The ITT population includes all subjects randomized. The Safety population includes all randomized subjects known to have taken at least one dose of randomized study drug. The Efficacy population includes all subjects in the safety population who also have at least one post-baseline ADAS-Cog and CIBIC+ assessment.

Source: C:\cdisc\_pilot\PROGRAMS\DRAFT\TFLs\adsl1.sas

21:02 Monday, June 26, 2006